NCT04027517 - A Study to Evaluate Efficacy and Safety of JTZ-951 Compared to Darbepoetin Alfa in Korean Renal Anemia Patients Receiving Hemodialysis. | Biotech Hunter

Enrollment

172

Participants

Timeline

Start Date

January 15, 2019

Primary Completion Date

February 23, 2021

Study Completion Date

February 23, 2021

Conditions

Anemia of Chronic Kidney Disease

Interventions

DRUG

JTZ-951

"Oral tablet~* Dose adjustments as maintenance dose is allowed according to the result of Hb level."

DRUG

Darbepoetin Alfa

"Intravenous administration~* Dose adjustments as maintenance dose is allowed according to the result of Hb level."

Trial Locations (1)

SMG-SNU Boramae Medical Center, Seoul